Bio-Rad Laboratories, Inc.Class A (BIO) Valuation
Historical valuation analysis based on 500 data points (2024-09-23 to 2026-09-21)
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics...
Bio-Rad Laboratories, Inc.Class A (BIO) currently trades at a P/E ratio of 60.26 (historical range: 20.86–62.34, median: 45.11), placing it at the 91th percentile — expensive relative to its history, P/S ratio of 3.93 (range: 2.38–4.10, 94th percentile — expensive relative to its history), EV/EBITDA of 3.98 (range: 2.12–55.64, 26th percentile).
Over the historical period (2024-09-23 to 2026-09-21), Bio-Rad Laboratories, Inc.Class A's P/E ratio has expanded by 109% over the observed period (from an average of 23.4 to 48.9).
Bio-Rad Laboratories, Inc.Class A trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 60.26 | 20.86 | 45.11 | 62.34 | 91th | expensive relative to its history |
| P/S Ratio | 3.93 | 2.38 | 3.14 | 4.10 | 94th | expensive relative to its history |
| EV/EBITDA | 3.98 | 2.12 | 4.72 | 55.64 | 26th | below its historical average |
| FCF Yield | 0.04 | 0.02 | 0.04 | 0.06 | 28th | above its historical average |
Bio-Rad Laboratories, Inc.Class A (BIO) Valuation & P/E History
Bio-Rad Laboratories, Inc.Class A (BIO) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry currently trading at $378.00 with a market capitalization of $10.1 billion. This page provides historical valuation analysis for BIO based on 500 data points covering 2024-09-23 to 2026-09-21. The P/E ratio of 60.26 is above the historical median of 45.11, placing BIO at the 91th percentile of its valuation range. The P/S ratio of 3.93 compares to a median of 3.14.
BIO Valuation Metrics & Historical Range
The valuation table above shows Bio-Rad Laboratories, Inc.Class A's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BIO is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BIO is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Bio-Rad Laboratories, Inc.Class A.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BIO Overvalued or Undervalued?
Bio-Rad Laboratories, Inc.Class A trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 70 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BIO is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BIO analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BIO trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.